Levetiracetam Krka

Levetiracetam, the active ingredient in Levetiracetam Krka, is an anticonvulsant presented as an oral tablet for oral use. It is indicated for the treatment of partial seizures, generalized tonic‑clonic seizures and myoclonic seizures in patients diagnosed with epilepsy.

GNH USA supplies Levetiracetam Krka as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide. The product is manufactured in the European Union and meets EU quality specifications.

Levetiracetam is an antiepileptic medication used to control various seizure types. - Partial seizures: reduces the frequency and severity of focal onset seizures, supporting better daily functioning. - Generalized tonic-clonic seizures: helps prevent convulsive episodes in patients with generalized epilepsy, lowering risk of injury. - Myoclonic seizures: decreases sudden muscle jerks associated with myoclonic epilepsy, improving quality of life. - Adjunct therapy for refractory epilepsy: used as an add‑on when seizures are not adequately controlled by other agents.

Levetiracetam may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Drowsiness: mild to moderate sedation that may affect alertness. - Dizziness: sensation of light‑headedness or imbalance, often transient. - Headache: transient cranial pain that may vary in intensity. - Fatigue: reduced energy levels and increased tiredness. - Irritability: mood changes, including increased agitation or restlessness. - Nausea: mild gastrointestinal upset, sometimes accompanied by stomach discomfort.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, hives, or anaphylaxis requiring immediate medical attention. - Mood disorders: emergence of depression, anxiety, or suicidal thoughts. - Hematologic abnormalities: decreased white blood cells, platelets, or anemia. - Stevens‑Johnson syndrome: severe skin eruption with blistering and mucosal involvement. - Hepatic dysfunction: significant elevation of liver enzymes indicating liver injury. - Psychosis: hallucinations, delusional thinking, or severe behavioral changes.

When prescribing Levetiracetam, clinicians should consider several precautionary measures to ensure safe use. - Renal function: adjust dosing in patients with impaired kidney function. - Psychiatric history: monitor for mood changes, depression, or suicidal ideation. - Concomitant CNS depressants: use caution as additive sedation may occur. - Pregnancy: evaluate risk‑benefit ratio; limited data are available. - Elderly patients: start at lower doses and monitor for adverse effects. - Store at ambient temperature: keep below 25 °C, protect from moisture, and retain in original packaging.

Levetiracetam may interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels, decreasing effectiveness. - Phenobarbital: can lower levetiracetam concentrations, risking breakthrough seizures.

Moderate Interactions (Monitor Closely): - Valproic acid: may increase levetiracetam levels, requiring observation for toxicity. - Other antiepileptics: combined use may enhance central nervous system depression. - Oral contraceptives: levetiracetam may slightly reduce hormonal efficacy; advise additional contraceptive measures.